Healthcare market research in India: a guide

How the Indian market is structured

India combines a very large generics and formulations industry with a provider landscape that spans corporate hospital chains, standalone nursing homes and single-specialty centres, government medical colleges and district hospitals, and an enormous retail pharmacy channel. Public financing has expanded through Ayushman Bharat PM-JAY and state insurance schemes, but a substantial share of retail medicine spending remains out of pocket, which makes affordability a live clinical conversation rather than a background assumption.

For research design the consequence is heterogeneity. The same therapy area can look like a premium private-pay market in a metro corporate chain and a price-led, scheme-funded market in a district hospital two hours away. A sample that does not deliberately span those settings will produce a confident answer about whichever one it over-represents.

Who the decision-makers are

The prescriber remains central, but the surrounding cast differs from Western markets. In corporate chains, purchase and formulary decisions involve hospital pharmacy, materials management and increasingly a formal procurement function; in standalone nursing homes, the owner-clinician is often all of those roles at once. Government procurement runs through tenders and rate contracts, with their own timelines and specification logic.

Two stakeholders are routinely under-researched. The retail chemist influences which brand of a given molecule actually leaves the counter, which matters enormously in a branded-generics market. And for chronic disease, the family member who manages adherence and pays for refills is frequently the real decision-maker — interviewing the patient alone can miss the economics entirely.

Reaching physicians across metro and tier-2 markets

Specialists concentrate in the major metros, and a metro-only sample is therefore easy to recruit and systematically misleading. Tier-2 and tier-3 cities carry a large share of patient volume and are increasingly where launch trajectories are decided, but the practice reality there is different: higher patient throughput, shorter consultations, more price sensitivity and less exposure to international guidelines.

Scheduling has to accommodate that. High-volume clinicians are reachable in narrow windows — early morning, between OPD sessions, late evening — and will give a tight 30 minutes far more reliably than a loose hour. Shorter, well-structured interviews with a wider geographic spread usually beat long interviews with whoever had time.

Language, moderation and fieldwork logistics

Most Indian specialists are comfortable discussing clinical topics in English, so English-language interviewing works well for physician research. It works much less well for patients, caregivers, nurses, pharmacy staff and clinicians in smaller practices, where moderation in Hindi, Marathi, Gujarati, Bengali, Tamil, Telugu, Kannada or Malayalam changes both the volume and the candour of what is said.

Logistics matter as much as language. Quantitative fieldwork should assume mobile-first completion and short modules. In-clinic work needs permission from the practice and realistic expectations about interruption. And translation is not only linguistic: symptom descriptions, adherence language and the vocabulary around cost and family decision-making need localising, not literal translating, or the instrument will measure comprehension instead of opinion.

Pricing, access and the payment mix

Pricing research in India has to carry the payment mix explicitly. For retail medicines, a large share of spending is out of pocket, so price sensitivity sits with the patient and family and is mediated by the prescriber's awareness of it. For hospitalisation, scheme and insurer coverage is more significant, and package rates under PM-JAY or state schemes set hard economic boundaries for what a hospital will adopt.

Layer on price regulation: the National List of Essential Medicines and the Drugs (Prices Control) Order set ceiling prices for scheduled formulations, which constrains the corridor a pricing study can meaningfully explore. Standard techniques still apply — Van Westendorp and Gabor-Granger for sensitivity, conjoint for trade-offs — but the stimulus has to reflect realistic out-of-pocket amounts and, where relevant, the scheme rate the hospital will be reimbursed.

Regulation and compliance

Three Indian frameworks sit alongside the international research codes. CDSCO regulates drugs, biologics and medical devices, which bounds what may be discussed about indicated use. The UCPMP code governs how industry interacts with healthcare professionals, which is why research must remain visibly non-promotional and separated from sales activity. The Digital Personal Data Protection Act sets consent, purpose-limitation and retention obligations for respondent data.

On top of these, most international sponsors still require EphMRA, BHBIA or Insights Association standards: documented consent before recording, conflict and confidentiality screening, adverse event and product complaint reporting inside an agreed window, and honoraria benchmarked to fair market value for Indian specialties rather than converted from another market's rate card.

Designing a sample that represents India

Build the sample frame on the dimensions that actually change behaviour, then quota against them deliberately rather than hoping recruitment balances itself.

Report findings against those cuts, not just as a national average. An all-India mean across a market this heterogeneous frequently describes nobody, and the segment differences are usually where the commercial decision actually lives.

• City tier: metro, tier-2 and tier-3, with a minimum per tier rather than a national total.
• Setting: corporate chain, standalone nursing home or single-specialty centre, government hospital or medical college.
• Region: north, west, south and east, because treatment norms and language differ meaningfully.
• Payment mix: proportion of the respondent's patients paying out of pocket versus covered by a scheme or insurer.
• Patient volume: high-throughput practices behave differently from low-volume ones in the same specialty.
• Channel stakeholders: include chemists, hospital pharmacy and procurement where the decision involves them.

Common mistakes in India fieldwork

The recurring errors are structural rather than technical. Metro-only samples, because they are easy. English-only moderation extended to patients and nurses, because it worked with physicians. Importing another market's payer model and asking questions about formulary tiers and prior authorisation that do not map onto how Indian coverage works.

Two more are worth naming. Ignoring the chemist in a branded-generics market leaves out the person who often determines which brand is dispensed. And treating a metro corporate hospital as a proxy for the private sector overlooks the very large number of standalone practices where the owner-clinician makes every decision, with completely different economics and far shorter purchase cycles.